Zoetis IncZTS
▲ PositiveRegulationrelevance
Emergency Use Authorization for Simparica Trio to treat screwworm infestations expands approved use, though temporary and no sales forecast.
Impact on stocks 1
Health Care
Zoetis IncZoetis Inc. received Emergency Use Authorization for Simparica Trio to treat New World screwworm infestations in dogs and puppies. The authorization comes one week after the company reported a 7% decline in U.S. revenue and an 11% drop in domestic companion-animal product sales. Simparica Trio was already approved as a monthly chewable for protection against heartworms, fleas, and ticks, and the emergency authorization gives veterinarians another option for addressing New World screwworm, whose larvae feed on living tissue and can cause severe injury or death without treatment. Zoetis did not disclose expected sales, pricing changes, or a revenue forecast associated with the expanded use, and the authorization is temporary, covering treatment rather than prevention. The company has also received emergency authorizations for Dectomax to prevent infestations in sheep, deer, swine, horses, lactating and dry dairy cows, and dairy replacement heifers, and conditional approval for Dectomax-CA1 injectable treatment in beef cattle.
Zoetis IncEmergency Use Authorization for Simparica Trio to treat screwworm infestations expands approved use, though temporary and no sales forecast.